Dashboard
Manage Tickers

FOLD


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-csx-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday
This CSX Analyst Turns Bullish; Here Are T...
09/18/2025 11:23:26

needham-upgrades-amicus-therapeutics-to-buy-announces-14-price-target
Needham Upgrades Amicus Therapeutics to Bu...
09/18/2025 10:00:55

Needham analyst Gil Blum upgrades Amicus Therapeutics (NASDAQ:FOLD) from Hold to Buy and announces $14 price target.

amicus-therapeutics-reports-4-year-muscle-function-and-biomarker-data-from-propel-study-of-cipaglucosidase-alfa--miglustat-in-late-onset-pompe-disease
Amicus Therapeutics Reports 4-Year Muscle ...
09/08/2025 13:05:49

Amicus Therapeutics (NASDAQ:FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarke...

amicus-therapeutics-affirms-fy2025-sales-guidance-of-607539m-644520m-vs-620675m-est
Amicus Therapeutics Affirms FY2025 Sales G...
07/31/2025 11:14:20

2025 Financial GuidanceAmicus reiterates its financial guidance for 2025, as follows:Total Revenue Growth115% to 22% Galafold R...

amicus-therapeutics-q2-adj-eps-001-beats-011-estimate-sales-154688m-beat-147399m-estimate
Amicus Therapeutics Q2 Adj. EPS $0.01 Beat...
07/31/2025 11:06:47

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

morgan-stanley-upgrades-amicus-therapeutics-to-overweight-raises-price-target-to-108
Morgan Stanley Upgrades Amicus Therapeutic...
07/17/2025 11:33:37

Morgan Stanley analyst Jeffrey Hung upgrades Amicus Therapeutics (NASDAQ:FOLD) from Equal-Weight to Overweight and raises th...

amicus-therapeutics-receives-approval-from-japans-ministry-of-health-labour-and-welfare-for-pombiliti--opfolda
Amicus Therapeutics Receives Approval From...
06/25/2025 11:05:29

amicus-therapeutics-announced-the-publication-of-a-post-hoc-analysis-of-data-from-the-ert-experienced-cohort-of-the-propel-study-of-cipaglucosidase-alfa-atga--miglustat-cipamig-in-adults-with-late-onset-pompe-disease-in-muscle-and-nerve
Amicus Therapeutics Announced The Publicat...
06/03/2025 11:13:06

PROPEL was a 52-week, double-blind randomized global study designed to assess the efficacy, safety, and tolerability of cipaglu...

ubs-maintains-buy-on-amicus-therapeutics-raises-price-target-to-22
UBS Maintains Buy on Amicus Therapeutics, ...
05/02/2025 22:37:55

UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $21 to $22.

goldman-sachs-maintains-neutral-on-amicus-therapeutics-lowers-price-target-to-9
Goldman Sachs Maintains Neutral on Amicus ...
05/02/2025 16:47:03

Goldman Sachs analyst Salveen Richter maintains Amicus Therapeutics (NASDAQ:FOLD) with a Neutral and lowers the price target...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/01/2025 12:05:58

amicus-therapeutics-sees-fy25-revenue-growth-of-17---24
Amicus Therapeutics Sees FY25 Revenue Grow...
05/01/2025 11:11:34

amicus-therapeutics-q1-adj-eps-003-beats-005-estimate-sales-12520m-miss-13586m-estimate
Amicus Therapeutics Q1 Adj. EPS $0.03 Beat...
05/01/2025 11:10:22

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For May 1, 2025
05/01/2025 08:32:37

reported-earlier-dimerix-and-amicus-therapeutics-sign-exclusive-us-license-agreement-for-dmx-200-in-fsgs-treatment
Reported Earlier, Dimerix And Amicus Thera...
05/01/2025 07:19:37

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) D...

amicus-therapeutics-earnings-preview
Amicus Therapeutics Earnings Preview
04/30/2025 16:01:30

wells-fargo-maintains-overweight-on-amicus-therapeutics-lowers-price-target-to-17
Wells Fargo Maintains Overweight on Amicus...
02/20/2025 13:35:34

Wells Fargo analyst Tiago Fauth maintains Amicus Therapeutics (NASDAQ:FOLD) with a Overweight and lowers the price target fr...

needham-reiterates-hold-on-amicus-therapeuticsto-hold
Needham Reiterates Hold on Amicus Therapeu...
02/20/2025 09:58:00

Needham analyst Gil Blum reiterates Amicus Therapeutics (NASDAQ:FOLD) from Hold to Hold.

amicus-therapeutics-2025-guidance-expects-total-revenue-growth-of-17-24-gross-margin-in-mid-80-and-gaap-net-income-positive-in-second-half
Amicus Therapeutics 2025 Guidance: Expects...
02/19/2025 12:03:47

2025 Financial GuidanceTo advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION